Sugi Predict

Sugi Predict / Compounds / Hki-357

Hki-357

Hki-357

SCHEMBL2134691

[2H]C([2H])([2H])N(C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c(C#N)cnc2cc1OCC)C([2H])([2H])[2H]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.93
▸ ERBB2 P04626 20/20 0.93
▸ STK25 O00506 1/20 0.72
▸ MAP2K7 O14733 1/20 0.72
▸ CHEK1 O14757 1/20 0.72
▸ GAK O14976 1/20 0.72
▸ EPHB6 O15197 1/20 0.72
▸ ABCC4 O15439 1/20 0.72
▸ MAP3K13 O43283 1/20 0.72
▸ NUAK1 O60285 1/20 0.72
▸ STK17B O94768 1/20 0.72
▸ STK10 O94804 1/20 0.72
▸ PRKD3 O94806 1/20 0.72
▸ ABCB11 O95342 1/20 0.72
▸ MAP4K4 O95819 1/20 0.72
▸ CHEK2 O96017 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ INSR P06213 1/20 0.72
▸ LCK P06239 1/20 0.72
▸ FYN P06241 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hki-357 SCHEMBL2129079 0.98 EGFR (0.94) EGFRERBB2STK25MAP2K7CHEK1
Hki-357 SCHEMBL2203420 0.96 EGFR (1.00) EGFRERBB2STK25MAP2K7CHEK1
Hki-357 SCHEMBL2203413 0.96 EGFR (1.00) EGFRERBB2STK25MAP2K7CHEK1
Hki-357 SCHEMBL29351355 0.96 EGFR (1.00) EGFRERBB2STK25MAP2K7CHEK1
Hki-357 SCHEMBL29478857 0.96 EGFR (1.00) EGFRERBB2STK25MAP2K7CHEK1
Hki-357 SCHEMBL29351364 0.96 EGFR (1.00) EGFRERBB2STK25MAP2K7CHEK1
SCHEMBL2131550 0.93 EGFR (0.81) EGFRERBB2
SCHEMBL4963947 0.91 EGFR (0.86) EGFRERBB2
SCHEMBL4963941 0.91 EGFR (0.86) EGFRERBB2
SCHEMBL18949451 0.89 EGFR (0.87) EGFRERBB2SRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748453-B2 Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof MEDOLUTION LIMITED (HK) 2014-06-10 — — US claimed
US-20120101116-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF MEDOLUTION LIMITED (US) 2012-04-26 — — US claimed
US-8748453-B2 Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof MEDOLUTION LIMITED (HK) 2014-06-10 — — US disclosed
EP-2445885-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF Medolution Limited (CN) 2012-05-02 — — EP disclosed
US-20120101116-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF MEDOLUTION LIMITED (US) 2012-04-26 — — US disclosed
WO-2010151710-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF MEDOLUTION LIMITED (CN) 2010-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101116-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF MAP4K2, MAP3K7, MAP3K1 EGFR 1263/4885ERBB2 464/4885STK25 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.